株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

消化性潰瘍:パイプライン製品の分析

Peptic Ulcers - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 213113
出版日 ページ情報 英文 57 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
消化性潰瘍:パイプライン製品の分析 Peptic Ulcers - Pipeline Review, H1 2016
出版日: 2016年06月15日 ページ情報: 英文 57 Pages
概要

消化性潰瘍とは、食道・胃の内側や小腸の上端部に生じる開放創・潰瘍のことを指します。主な症状として、吐き気・嘔吐や、原因不明の体重減少、食欲の変動、腹痛などが挙げられます。主なリスク要因には、喫煙やアルコール依存症などがあります。主な治療法といて、抗生物質や酸遮断薬、制酸剤、プロトンポンプ阻害剤などがあります。

当レポートでは、世界各国での消化性潰瘍治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

消化性潰瘍の概要

治療薬の開発

  • 消化性潰瘍向けパイプライン製品:概要
  • 消化性潰瘍向けパイプライン製品:比較分析

各企業で開発中の消化性潰瘍治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

消化性潰瘍治療薬:開発中の製品の一覧(企業別)

消化性潰瘍治療薬の開発に従事している企業

  • Ache Laboratorios Farmaceuticos S/A
  • アステラス製薬
  • ChoDang Pharm Co., Ltd.
  • Daewoong Pharmaceutical Co., Ltd.
  • Kukje Pharmaceutical Industry Co., Ltd.
  • RaQualia Pharma Inc.
  • Sequella, Inc.
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Sinil Pharmaceutical Co., Ltd
  • Yooyoung Pharmaceutical Co., Ltd.

消化性潰瘍:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

消化性潰瘍治療薬:開発が休止状態の製品

消化性潰瘍治療薬:開発が中止された製品

消化性潰瘍関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース
  • ■付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8193IDB

Summary

Global Markets Direct's, 'Peptic Ulcers - Pipeline Review, H1 2016', provides an overview of the Peptic Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peptic Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Peptic Ulcers
  • The report reviews pipeline therapeutics for Peptic Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Peptic Ulcers therapeutics and enlists all their major and minor projects
  • The report assesses Peptic Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Peptic Ulcers

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Peptic Ulcers
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Peptic Ulcers pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Peptic Ulcers Overview
  • Therapeutics Development
    • Pipeline Products for Peptic Ulcers - Overview
  • Peptic Ulcers - Therapeutics under Development by Companies
  • Peptic Ulcers - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Peptic Ulcers - Products under Development by Companies
  • Peptic Ulcers - Companies Involved in Therapeutics Development
    • Ache Laboratorios Farmaceuticos S/A
    • Astellas Pharma Inc.
    • ChoDang Pharm Co., Ltd.
    • Daewoong Pharmaceutical Co., Ltd.
    • Kukje Pharmaceutical Industry Co., Ltd.
    • RaQualia Pharma Inc.
    • Sequella, Inc.
    • Sihuan Pharmaceutical Holdings Group Ltd.
    • Sinil Pharmaceutical Co., Ltd
    • Yooyoung Pharmaceutical Co., Ltd.
  • Peptic Ulcers - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (ecabet + ranitidine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (lansoprazole + omeprazole) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anaprazole sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-6537 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWJ-206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KJ-14001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PDI-39 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PMKS-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00000774 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SI-001002 SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Proton Pump for Peptic Ulcers - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Gastric Ulcers - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SQ-109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YYD-601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Peptic Ulcers - Dormant Projects
  • Peptic Ulcers - Discontinued Products
  • Peptic Ulcers - Product Development Milestones
    • Featured News & Press Releases
      • Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
      • Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers
      • Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
      • Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
      • Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
      • Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
      • Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
      • Jun 01, 2007: AstraZeneca's Prilosec Patents Upheld By Court
      • Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Peptic Ulcers, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Peptic Ulcers - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016
  • Peptic Ulcers - Pipeline by Astellas Pharma Inc., H1 2016
  • Peptic Ulcers - Pipeline by ChoDang Pharm Co., Ltd., H1 2016
  • Peptic Ulcers - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016
  • Peptic Ulcers - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H1 2016
  • Peptic Ulcers - Pipeline by RaQualia Pharma Inc., H1 2016
  • Peptic Ulcers - Pipeline by Sequella, Inc., H1 2016
  • Peptic Ulcers - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016
  • Peptic Ulcers - Pipeline by Sinil Pharmaceutical Co., Ltd, H1 2016
  • Peptic Ulcers - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Peptic Ulcers - Dormant Projects, H1 2016
  • Peptic Ulcers - Dormant Projects (Contd..1), H1 2016
  • Peptic Ulcers - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Peptic Ulcers, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top